Read, Watch or Listen

A Memorial Sloan Kettering Cancer Center study tested dostarlimab, an immunotherapy drug, as a standalone treatment for 103 patients with rectal tumors responsive to immunotherapy. The trial aimed to avoid the harsh side effects of traditional treatments like surgery, radiation, and chemotherapy. The study focused on a small subset of patients (2-3%) whose cancers are known to respond to immunotherapy. Results were not included in the provided text.

Prepared by Olivia Bennett and reviewed by editorial team.